S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
S&P 500   4,002.87
DOW   32,560.60
QQQ   310.34
Game-Changing News For Tesla Investors 
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These 3 Stocks Are Ready To Rally Out Of Bullish Bases
Microsoft Is The New Safe Haven
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
These Are The Top 3 Large Caps For Yield And Dividend Growth 
A Guy Is Using ChatGPT to Turn $100 Into a Business Making as Much Money as Possible. Here Are the First 4 Steps the AI Chatbot Gave Him.
The Stock That Is Flying Under Wall St. Radar (Ad)pixel
DOW New Hghs Coming Sooner Than Later
On Holding AG Sprints Higher on Margin Expansion and Guidance
NASDAQ:TCRX

TScan Therapeutics - TCRX Stock Forecast, Price & News

$2.56
-0.11 (-4.12%)
(As of 03/21/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.54
▼
$2.73
50-Day Range
$1.73
▼
$3.32
52-Week Range
$1.45
▼
$4.56
Volume
9,728 shs
Average Volume
49,540 shs
Market Capitalization
$62.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.00

TScan Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
485.9% Upside
$15.00 Price Target
Short Interest
Healthy
1.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$4,263 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($3.13) to ($3.11) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

297th out of 983 stocks

Biological Products, Except Diagnostic Industry

49th out of 163 stocks

See Top Rated MarketRank™ Stocks Here

TCRX stock logo

About TScan Therapeutics (NASDAQ:TCRX) Stock

TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Receive TCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRX Stock News Headlines

March 15, 2023 | marketwatch.com
TScan Therapeutics Shares Rise 8% After First Patient Dosed With TSC-101
March 14, 2023 | finance.yahoo.com
TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies
March 22, 2023 | Upexi, Inc (Ad)
The Stock That Is Flying Under Wall St. Radar
With The Founder OF XPO Logistics Leading The Way This Nasdaq Company is Ready and GOING!pixel
March 14, 2023 | americanbankingnews.com
TScan Therapeutics, Inc. (NASDAQ:TCRX) to Post Q1 2023 Earnings of ($0.70) Per Share, Jefferies Financial Group Forecasts
March 14, 2023 | americanbankingnews.com
Q1 2023 EPS Estimates for TScan Therapeutics, Inc. Decreased by HC Wainwright (NASDAQ:TCRX)
March 13, 2023 | finance.yahoo.com
TScan Therapeutics to Participate in the Barclays Global Healthcare Conference
March 12, 2023 | americanbankingnews.com
TScan Therapeutics' (TCRX) Buy Rating Reiterated at HC Wainwright
March 10, 2023 | msn.com
TScan Therapeutics's Return On Capital Employed Insights
March 22, 2023 | Upexi, Inc (Ad)
The 1 Stock To Watch In This Market.
This NASDAQ Stock Has Been On The Move In 2023 And It Looks Like Its Far From Over!pixel
March 10, 2023 | finance.yahoo.com
TScan Therapeutics Full Year 2022 Earnings: Misses Expectations
March 9, 2023 | markets.businessinsider.com
Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and TScan Therapeutics (TCRX)
March 9, 2023 | markets.businessinsider.com
H.C. Wainwright Keeps Their Buy Rating on TScan Therapeutics (TCRX)
March 8, 2023 | msn.com
TScan Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $3.09M misses by $1.01M
March 8, 2023 | finance.yahoo.com
TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones
March 1, 2023 | finance.yahoo.com
TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference
February 21, 2023 | finance.yahoo.com
TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference
January 23, 2023 | markets.businessinsider.com
TScan Announces FDA Clearance Of 3 INDs For Solid Tumors
January 23, 2023 | msn.com
TScan stock rises ~15% on FDA nod to start trials of cancer drugs
January 23, 2023 | finance.yahoo.com
TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
January 5, 2023 | finance.yahoo.com
TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress
December 12, 2022 | finance.yahoo.com
TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022
December 9, 2022 | finance.yahoo.com
A number of insiders bought TScan Therapeutics, Inc. (NASDAQ:TCRX) stock last year, which is great news for shareholders
December 1, 2022 | finance.yahoo.com
TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe
November 22, 2022 | finance.yahoo.com
TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference
November 11, 2022 | finance.yahoo.com
TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting
November 9, 2022 | finanznachrichten.de
TScan Therapeutics, Inc.: TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
November 9, 2022 | finance.yahoo.com
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
See More Headlines
Receive TCRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TScan Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TCRX Company Calendar

Last Earnings
11/10/2021
Today
3/21/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCRX
CUSIP
N/A
CIK
1783328
Web
www.tscan.com
Phone
857-399-9500
Fax
N/A
Employees
104
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.00
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+485.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.75)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-66,220,000.00
Net Margins
-489.22%
Pretax Margin
-489.26%
Return on Equity
-53.68%
Return on Assets
-38.66%

Debt

Debt-to-Equity Ratio
0.29
Current Ratio
7.17
Quick Ratio
7.17

Sales & Book Value

Annual Sales
$13.53 million
Price / Sales
4.58
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.10 per share
Price / Book
0.62

Miscellaneous

Outstanding Shares
24,230,000
Free Float
22,942,000
Market Cap
$62.03 million
Optionable
Not Optionable
Beta
0.44

Key Executives

  • Mr. David P. Southwell (Age 62)
    Pres, CEO & Director
    Comp: $861.43k
  • Mr. Brian Michael Silver J.D. (Age 54)
    Sr. VP, CFO & Treasurer
    Comp: $600.13k
  • Dr. Gavin MacBeath Ph.D. (Age 53)
    Chief Scientific & Operations Officer
    Comp: $571.84k
  • Dr. Stephen J. Elledge Ph.D.
    Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Tomasz Kula Ph.D.
    Co-Founder & Member of Advisory Board
  • Mr. Ray Lockard
    VP of Technical Operations & Quality
  • Ms. Heather Savelle
    VP of Investor Relations
  • Dr. Zoran Zdraveski J.D. (Age 53)
    Ph.D., Chief Legal Officer & Company Sec.
  • Ms. Ann Hargraves
    VP of HR
  • Dr. William Desmarais M.B.A. (Age 53)
    Ph.D., Chief Bus. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













TCRX Stock - Frequently Asked Questions

Should I buy or sell TScan Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TScan Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TCRX shares.
View TCRX analyst ratings or view top-rated stocks.

What is TScan Therapeutics' stock price forecast for 2023?

1 Wall Street research analysts have issued 12 month target prices for TScan Therapeutics' shares. Their TCRX share price forecasts range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next year. This suggests a possible upside of 485.9% from the stock's current price.
View analysts price targets for TCRX or view top-rated stocks among Wall Street analysts.

How have TCRX shares performed in 2023?

TScan Therapeutics' stock was trading at $1.55 at the beginning of the year. Since then, TCRX stock has increased by 65.2% and is now trading at $2.56.
View the best growth stocks for 2023 here.

When is TScan Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our TCRX earnings forecast.

How were TScan Therapeutics' earnings last quarter?

TScan Therapeutics, Inc. (NASDAQ:TCRX) posted its earnings results on Wednesday, November, 10th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.19. The business earned $2.41 million during the quarter. TScan Therapeutics had a negative net margin of 489.22% and a negative trailing twelve-month return on equity of 53.68%.

What ETF holds TScan Therapeutics' stock ?

BlackRock Future Health ETF holds 1,378 shares of TCRX stock, representing 0.07% of its portfolio.

When did TScan Therapeutics IPO?

(TCRX) raised $100 million in an initial public offering (IPO) on Friday, July 16th 2021. The company issued 6,250,000 shares at a price of $15.00-$17.00 per share.

What is TScan Therapeutics' stock symbol?

TScan Therapeutics trades on the NASDAQ under the ticker symbol "TCRX."

Who are TScan Therapeutics' major shareholders?

TScan Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Tang Capital Management LLC (2.14%), Morgan Stanley (0.18%) and Millennium Management LLC (0.08%). Insiders that own company stock include Brian M Silver, David P Southwell, Gavin Macbeath and Zoran Zdraveski.
View institutional ownership trends.

How do I buy shares of TScan Therapeutics?

Shares of TCRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TScan Therapeutics' stock price today?

One share of TCRX stock can currently be purchased for approximately $2.56.

How much money does TScan Therapeutics make?

TScan Therapeutics (NASDAQ:TCRX) has a market capitalization of $62.03 million and generates $13.53 million in revenue each year. The company earns $-66,220,000.00 in net income (profit) each year or ($2.75) on an earnings per share basis.

How many employees does TScan Therapeutics have?

The company employs 104 workers across the globe.

How can I contact TScan Therapeutics?

TScan Therapeutics' mailing address is 830 WINTER STREET, WALTHAM MA, 02451. The official website for the company is www.tscan.com. The company can be reached via phone at 857-399-9500 or via email at tscan@argotpartners.com.

This page (NASDAQ:TCRX) was last updated on 3/22/2023 by MarketBeat.com Staff